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Fibroblast growth factor 23 (FGF23) exerts its effect by
binding to its cognate FGF receptor 1 (FGFR1) in the presence
of its co-receptor Klotho. Parathyroid glands express both
FGFR1 and Klotho, and FGF23 decreases parathyroid
hormone gene expression and hormone secretion directly. In
uremic patients with secondary hyperparathyroidism (SHPT),
however, parathyroid hormone secretion remains elevated
despite extremely high FGF23 levels. To determine the
mechanism of this resistance, we measured the expression
of Klotho, FGFR1, and the proliferative marker Ki67 in
7 normal and 80 hyperplastic parathyroid glands from uremic
patients by immunohistochemistry. All uremic patients had
severe SHPT along with markedly high FGF23 levels.
Quantitative real-time reverse transcription PCR showed that
the mRNA levels for Klotho and FGFR1correlated significantly
with their semi-quantitative immunohistochemical intensity.
Compared with normal tissue, the immunohistochemical
expression of Klotho and FGFR1 decreased, but Ki67
expression increased significantly in hyperplastic parathyroid
glands, particularly in glands with nodular hyperplasia.
These results suggest that the depressed expression of
the Klotho–FGFR1 complex in hyperplastic glands underlies
the pathogenesis of SHPT and its resistance to extremely
high FGF23 levels in uremic patients.
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Secondary hyperparathyroidism (SHPT) is a common
complication of chronic kidney disease. Phosphate retention,
hypocalcemia, and calcitriol deficiency have long been
considered to contribute to the pathogenesis of SHPT.1–3
In addition, recent data suggest that fibroblast growth factor
23 (FGF23), a novel phosphaturic hormone, has a central role
in the progressive decline of calcitriol levels and in the
concomitant parathyroid hormone (PTH) hypersecretion in
chronic kidney disease.4–6
FGF23 is a 32 kD protein that is mainly produced by
osteocytes,7 and it exerts its hormonal effects by binding to
its cognate fibroblast growth factor receptor 1 (FGFR1) in the
presence of its obligatory co-receptor, Klotho.8,9 Klotho is a
transmembrane protein that determines the tissue specificity
of FGF23. In the kidney, FGF23 interacts with the
Klotho–FGFR1 complex present in the distal tubule,10 and
thereby presumably inhibits sodium-dependent transporter
and 1a-hydroxylase (CYP27B1) activities in the proximal
tubule, leading to phosphaturia and reduced synthesis of
calcitriol.11,12 In patients with chronic kidney disease, FGF23
levels increase as kidney function declines to help maintain
normal serum phosphate levels, but this results in the
aggravation of SHPT because of decreased feedback inhibi-
tion by calcitriol.4–6 Once on dialysis, serum FGF23 levels
markedly increase in response to hyperphosphatemia and
calcitriol therapy.13–15
Importantly, the parathyroid gland also expresses both
FGFR1 and Klotho and is a target organ for FGF23.16,17
Recent studies have shown that FGF23 directly decreases PTH
gene expression and secretion. These data suggest that the
direct action of FGF23 on PTH secretion is in contrast to its
indirect action by inhibition of renal calcitriol production. It
is, however, noteworthy that in uremic patients undergoing
dialysis, such an indirect effect of FGF23 may be less evident,
as renal production of calcitriol is substantially impaired and
active vitamin D sterols are frequently used to control SHPT.
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Thus, extremely elevated FGF23 levels would be expected to
decrease serum PTH levels in uremic patients. However, in
these patients, PTH secretion remains elevated despite
extremely high FGF23 levels.14,15 A similar paradox has been
observed in refractory SHPT, in which parathyroid glands do
not respond to calcium supplementation and calcitriol
therapy, which should decrease PTH secretion. In the past,
such a resistance to medical treatment has been explained by
a decrease in the expression of calcium-sensing receptor and
vitamin D receptor, particularly in glands with nodular
hyperplasia, which is a more severe form of parathyroid
hyperplasia.18–22
In the present study, we examined the expression of
Klotho and FGFR1 in surgically excised parathyroid glands of
uremic patients and compared it with the expression in
normal human parathyroid tissue. The recognition of
abnormal Klotho–FGFR1 complex expression would provide
a new insight into the mechanisms involved in dysregulated
PTH secretion and parathyroid cell proliferation in uremic
patients with extremely high FGF23 levels.
RESULTS
Patient characteristics
Parathyroid tissue specimens were obtained from 5 patients
with normal kidney function and 23 dialysis patients with
SHPT. Clinical characteristics of the patients included in the
study are shown in Table 1. Control patients had normal
levels of serum whole PTH and FGF23, whereas all uremic
patients had severe SHPT requiring parathyroidectomy and
showed extremely high levels of serum FGF23, as reported
previously.23 Serum calcium, phosphate, and alkaline phos-
phatase levels were also significantly higher in dialysis
patients than in control patients. Nearly all patients with
SHPT (21 of 23) were treated with vitamin D sterols at the
time of parathyroidectomy, and 43 percent (10 of 23) had a
history of treatment with cinacalcet hydrochloride.
Histology and weight of removed parathyroid glands
A total of 7 normal parathyroid glands and 80 hyperplastic
parathyroid glands were obtained from the participating
patients. All normal parathyroid glands showed clusters of
parenchymal cells mixed with a considerable amount of
adipose tissue. Hyperplastic parathyroid glands were divided
into two types: diffuse hyperplasia (n¼ 19) and nodular
hyperplasia (n¼ 61). Diffuse hyperplasia was defined as an
increased number of parenchymal cells with normal lobular
structures, and nodular hyperplasia was defined as at least
one well-circumscribed, encapsulated, and virtually fat cell-
free accumulation of parenchymal cells.24 All uremic patients
with SHPT had at least one hyperplastic gland with nodular
hyperplasia. The weight of glands with nodular hyperplasia
(672±80mg) was significantly higher than those with diffuse
hyperplasia (172±41mg, Po0.001).
Immunohistochemical expression of Klotho, FGFR1, and Ki67
Representative immunohistochemical staining of Klotho,
FGFR1, and Ki67 is shown in Figure 1. Ki67 is a proliferation
marker expressed in all phases of the cell cycle. In normal
glands, expression of Klotho and FGFR1 revealed distinct
staining along the parathyroid cell surface (Figure 1a and f),
suggesting that the parathyroid is a target organ for FGF23 in
humans also. In contrast, the expression of these proteins was
substantially reduced in hyperplastic parathyroid glands from
uremic patients, particularly in glands with nodular hyper-
plasia (Figure 1b–d, g–i). Ki67 expression showed mainly
nuclear localization, and its positive cells were evidently
increased in hyperplastic parathyroid glands compared with
normal glands (Figure 1k–n). Interestingly, careful evaluation
of serial sections revealed that expression of Klotho and
FGFR1 were virtually negative in parathyroid cells of nodular
lesions, whereas cells outside such lesions showed weak but
definitive positive staining (Figure 2a, b, d–g). A serial section
of the gland showed significantly increased Ki67-positive cells
in the nodular lesion compared with that in the outside area
(Figure 2c, h and i).
We scored the immunohistochemical signals of Klotho,
FGFR1, and Ki67 as described previously to perform a semi-
quantitative analysis.21 To confirm the validity of the semi-
quantification, we measured Klotho and FGFR1 mRNA levels
by quantitative real-time reverse transcription PCR in
aliquots from 41 different parathyroid glands. In these
patients, half of the surgically removed parathyroid glands
were used for immunohistochemistry and the other half were
used for real-time reverse transcription PCR. Linear regres-
sion analysis showed that immunohistochemical expression
of Klotho and FGFR1 correlated significantly with the
respective mRNA levels (r¼ 0.34, P¼ 0.028; and r¼ 0.36,
P¼ 0.021, respectively).
Next, we compared the semi-quantitative immunohisto-
chemical expression of Klotho, FGFR1, and Ki67 in
hyperplastic parathyroid glands obtained from uremic
patients with that in normal parathyroid tissue. We found
that both Klotho and FGFR1 scores decreased significantly in
uremic hyperplastic glands compared with normal tissue, and
that these trends were more pronounced in glands with
nodular hyperplasia (Figure 3a and b). Ki67 scores increased
significantly in glands with nodular hyperplasia compared
with either normal tissue or glands with diffuse hyperplasia
Table 1 | Baseline characteristics of the study population
Variable
Normal
(N=5)
SHPT
(N=23) P-value
Age (years) 67±2 54±3 0.002
Sex (male/female) 3/2 9/14 0.36
Duration of dialysis (months) NA 135±12 —
BUN (mg/dl) 15.3±2.2 60.0±3.7 o0.001
Creatinine (mg/dl) 0.86±0.08 11.19±0.56 o0.001
Calcium (mg/dl) 9.45±0.15 9.98±0.10 0.019
Phosphate (mg/dl) 3.90±0.32 6.08±0.30 o0.001
Alkaline phosphatase (U/l) 196±19 704±189 0.014
PTH(1–84) (pg/ml) 19±3 583±155 0.001
FGF23 (pg/ml) 37±13 12,629±2697 o0.001
BUN, blood urea nitrogen; FGF23, fibroblast growth factor 23; PTH, parathyroid
hormone; SHPT, secondary hyperparathyroidism.
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(Figure 3c). Ki67 score positively correlated with parathyroid
gland weight (r¼ 0.33, P¼ 0.003). Notably, there was a
significant correlation between Klotho and FGFR1 scores
(r¼ 0.71, Po0.001). This agrees with the fact that Klotho is
co-expressed with FGFR1.16 Klotho score was negatively
correlated with parathyroid gland weight (r¼0.24,
P¼ 0.033), and there was a nearly significant negative
correlation between FGFR1 score and parathyroid gland
weight (r¼0.21, P¼ 0.057). However, no significant
correlation was found between either Klotho or FGFR1 score
with Ki67 score.
DISCUSSION
In the present study, we evaluated Klotho and FGFR1
expression in parathyroid glands from uremic patients with
severe SHPT and from control patients with normal kidney
function, and showed that these expressions were signifi-
cantly downregulated in hyperplastic parathyroid glands
compared with normal parathyroid tissue. Furthermore, the
reduction in Klotho and FGFR1 expression was more
remarkable in glands with nodular hyperplasia than those
with diffuse hyperplasia.
FGF23 is a hormone that has a broader role in the
pathogenesis of alterations in mineral and bone metabolism25
by interacting with FGFR in the presence of Klotho.8,9 Klotho
directly binds with FGFR1c, 3c, and 4, and increases their
affinity to FGF23,8 whereas Klotho-dependent FGF23 signal-
ing defined by upregulation of the gene, early growth
responsive 1 (Egr-1), is restricted to interaction with
FGFR1c.9 Indeed, a recent study showed that neither FGFR3
nor FGFR4 is the principal mediator of FGF23 effects in the
kidney, suggesting that the Klotho–FGFR1 complex is the
main target for FGF23.10
Importantly, Klotho and FGFR1 are also co-expressed in
parathyroid glands.16 A previous study showed that FGF23
administration increases Egr-1 expression in the parathyroid
glands, implying that the parathyroid is a physiological target
for FGF23.8 A subsequent study using rats and in vitro
parathyroid cultures showed that FGF23 suppresses PTH
secretion.16 Other researchers have also reported similar
findings using primary bovine parathyroid cell cultures.17
Thus, it is clear that FGF23 is a negative regulator of PTH
secretion at least in normal physiology. Nevertheless, in
uremic patients undergoing dialysis therapy, PTH hyperse-
cretion and parathyroid cell proliferation is observed despite
elevated FGF23 levels.14,15 In this context, our finding that
the Klotho–FGFR1 complex is severely depressed in hyper-
plastic glands may shed light on the inability of extremely
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Figure 1 |Representative immunohistochemical staining of Klotho, fibroblast growth factor receptor 1 (FGFR1), and Ki67. (a–e)
Klotho staining (e; negative control); (f–j) FGFR1 staining (j; negative control); (k–n) Ki67 staining. (a, e, f, j, k) Normal parathyroid glands;
(b, g, l) diffuse parathyroid hyperplasia; (c, d, h, i, m, n) nodular parathyroid hyperplasia. Note the distinct staining of Klotho and FGFR1
along the cell surface in normal parathyroid glands. These expressions were substantially reduced in hyperplastic glands from uremic
patients, particularly in glands with nodular hyperplasia. Ki67-positive cells were evidently increased in uremic parathyroid hyperplasia. Such
an increase in Ki67-positive cells was particularly remarkable in nodular hyperplasia. Each area was scored as follows: grade 3, (a and f);
grade 2 (b and g); grade 1 (c and h); and grade 0 (d and i). Original magnifications: (a–j),  400; (k–n),  200. Bars¼ 100 mm.
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high FGF23 levels in sufficiently suppressing PTH secretion
in uremic patients. Recent studies suggest that FGF23 levels
increase as kidney function declines and are associated with
early and progressive calcitriol deficiency, and thus, may
contribute to the development of SHPT.4–6 In addition,
progressive depression of the Klotho–FGFR1 complex in
hyperplastic parathyroid glands may also have a role in SHPT
progression by inducing resistance to the inhibitory effect of
FGF23 on PTH secretion. In this study, however, we were
unable to directly confirm that the depressed expression of
Klotho and FGFR1 cause functional impairment of FGF23 on
the parathyroid glands. Future experimental studies are
needed to investigate fully the mechanisms underlying the
resistance of PTH hypersecretion to extremely high FGF23
levels in uremia. Specifically, whether or not systemic or local
upregulation of Klotho could mediate abnormal PTH
secretion and parathyroid cell proliferation is of interest
and worthy of further research.
The mechanism by which Klotho and FGFR1 expression is
reduced in uremic parathyroid hyperplasia is unclear. A
similar reduction in Klotho expression also occurs in
parathyroid adenoma from patients with primary hyperpar-
athyroidism.26 In that study, parathyroid Klotho mRNA
levels were inversely correlated to serum calcium level, which
is in agreement with a previous study showing that low
extracellular calcium is a stimulus for Klotho-mediated PTH
secretion.27 Relevantly, Klotho expression is also decreased in
the kidney obtained from chronic kidney disease patients.28
Studies in animal models have shown that systemic
administration of calcitriol or phosphorus-restricted diet
enhanced the renal expression of Klotho.29,30 Whether these
factors modulate the expression of Klotho and/or FGFR1 in
the parathyroid glands needs to be determined in future
research.
Our study also showed that even in the same patient, both
Klotho and FGFR1 expressions were more severely reduced in
nodular hyperplasia compared with diffuse hyperplasia.
Thus, it is clear that the severity of parathyroid hyperplasia
itself is associated with a reduction in the Klotho–FGFR1
complex in uremic patients. In the past, progressive
reduction in calcium-sensing receptor and vitamin D
receptor expression has been observed during the course of
parathyroid hyperplasia.18–22 A reduction in vitamin D
receptor expression may reportedly precede the onset of
parathyroid cell proliferation,31 and more recent studies
suggest that activation of the epidermal growth factor
receptor by tumor growth factor-a is the cause for both
hyperplastic growth and vitamin D receptor reduction.32 On
the other hand, reduced calcium-sensing receptor in the
parathyroid glands may follow the development of hyper-
plasia and then contribute to further parathyroid growth.33
Future studies should elucidate whether depressed expression
of the Klotho–FGFR1 complex has a role in the pathogenesis
of SHPT or it is only a secondary change caused by the
progression of parathyroid hyperplasia.
We previously reported that serum FGF23 levels predict
future refractory SHPT in dialysis patients.14,15 Although the
mechanism of this finding is unclear, it is possible that
chronic phosphate retention, as reflected by elevated FGF23
levels, may contribute to further progression of parathyroid
hyperplasia, because high phosphate level directly stimulates
PTH secretion and parathyroid cell proliferation.34,35 An-
other possibility is that high levels of FGF23 at baseline may
be a consequence of prolonged active vitamin D administra-
tion for severe hyperparathyroidism,13 which may be related
to future resistance to vitamin D therapy. Furthermore, the
results of this study propose that increased levels of FGF23
may reflect depression of the Klotho–FGFR1 complex, which
is associated with a more severe form of parathyroid
hyperplasia. These possibilities should be examined in future
studies.
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Figure 2 | Immunohistochemical staining of nodular lesions
surrounded by diffuse hyperplastic parathyroid tissue. (a, d, e)
Klotho staining; (b, f, g) fibroblast growth factor receptor 1
(FGFR1) staining; (c, h, i) Ki67 staining. Boxed areas are shown at
higher magnification to right of each frame, as indicated. Both
Klotho and FGFR1 expressions were markedly decreased in
nodular areas, whereas diffuse hyperplastic cells outside the
nodular lesion showed weak but definitive positive staining.
Ki67-positive cells were observed predominantly in nodular areas.
Original magnification: (a–c),  100; (d–i),  400. Bars¼ 100mm.
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Finally, we did not find a significant association of either
Klotho or FGFR1 expression with parathyroid cell prolifera-
tion as evaluated by Ki67 score, although the expression of
the Klotho–FGFR1 complex was markedly downregulated in
parallel with the severity of parathyroid hyperplasia and an
increase in parathyroid gland weight. The precise reason for
these findings is unclear; however, it is possible that the
inclusion of patients who have a history of cinacalcet
treatment may have influenced the results, as calcimimetics
prevent excessive parathyroid cell proliferation and gland
hyperplasia in uremic rats.36,37 Further studies are needed to
examine whether FGF23 mediates parathyroid cell prolifera-
tion in the presence of the Klotho–FGFR1 complex and
whether such an effect is altered in uremia.
In conclusion, Klotho and FGFR1 expression decreased
significantly in uremic parathyroid hyperplasia, particularly
in glands with nodular hyperplasia. The results of this study
suggest that the depressed expression of the Klotho–FGFR1
complex in hyperplastic glands may explain, at least in part,
the resistance to extremely high FGF23 levels that would be
expected to decrease the serum PTH levels. Additional
studies are needed to determine whether downregulation of
the Klotho–FGFR1 complex has a role in abnormal PTH
secretion and parathyroid growth in uremia. Further insights
into the FGF23–Klotho–FGFR1 system is important in
understanding the role of FGF23 in the pathogenesis of
SHPT, and in developing therapeutic approaches to treat
SHPT in uremic patients who have extremely elevated FGF23
levels.
MATERIALS AND METHODS
Parathyroid gland tissues
Normal parathyroid glands were obtained in conjunction with
thyroid surgery from patients with normal kidney function, and
hyperplastic parathyroid glands were obtained from dialysis patients
with SHPT who underwent total parathyroidectomy with auto-
transplantation. According to the guidelines released by the Japanese
Society for Dialysis Therapy,38 the indications for parathyroidect-
omy were the presence of severe hyperparathyroidism (persistent
high serum intact PTH levels 4500 pg/ml) associated with
hyperphosphatemia (serum phosphate 46.0mg/dl) and/or hyper-
calcemia (serum calcium 410.0mg/dl) that was refractory to
medical therapy. This study adhered to the principles of the
Declaration of Helsinki and was approved by the ethical committee
of the Kobe University School of Medicine. All patients provided an
informed consent.
Antibodies
A polyclonal anti-human Klotho antibody was kindly provided by
Kyowa Hakko Kirin (Tokyo, Japan). This antibody was generated by
immunizing rabbits with a synthesized peptide (PLQPATGDVASD-
SYNNVFRDT) corresponding to a sequence in the human Klotho
protein (amino acids 116–138). Affinity-purified antibody was
obtained by extraction from antiserum using the peptide immobi-
lized on agarose gel (SulfoLink kit; Pierce, Rockford, IL, USA). A
rabbit anti-FGFR1 polyclonal antibody was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), and a mouse
monoclonal anti-human Ki67 antibody was purchased from DAKO
(Glostrup, Denmark).
Immunohistochemistry
Parathyroid glands were fixed in 10% formalin and embedded in
paraffin. The sections (3 mm) were deparaffinized in xylene and
rehydrated through an ethanol series. Sections were heated in a
microwave for 20min in Target Retrieval Solution at pH 6.0
(DAKO) for Klotho staining and in 0.01mmol/l citrate buffer at pH
6.0 for Ki67 staining. Endogenous peroxidase was inactivated with
hydrogen peroxide for 5min. After blocking with 10% goat serum
for 15min, the sections were incubated with anti-Klotho antibody
(1:2500 dilution, 60min), anti-FGFR1 antibody (1:150 dilution,
30min), and anti-Ki67 antibody (1:75 dilution, 30min). Universal
Negative Control Rabbit (DAKO) was used as a negative control.
Sections for Klotho staining were incubated for 30min with
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Figure 3 | Semi-quantification expression of Klotho, fibroblast growth factor receptor 1 (FGFR1), and Ki67 in parathyroid tissue of
each group. The values shown are means±s.e.m. *Po0.1; **Po0.05; ***Po0.01; ****Po0.001.
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peroxidase-labeled polymer conjugated to goat anti-rabbit immuno-
globulins (EnVision System/HRP; DAKO), whereas sections for
FGFR1 and Ki67 staining were incubated with anti-rabbit/mouse
secondary antibody for 15min and with streptavidin–horseradish
peroxidase for 15min (LSAB2 System-HRP; DAKO). Finally, all the
sections were stained with 3,30-diaminobenzidine tetrahydrochlor-
ide for 5min and counterstained with hematoxylin for 1min. Every
step was followed by three washes with phosphate-buffered saline
for 5min, and all the procedures were performed at room
temperature.
Semi-quantification
Semi-quantitative immunohisochemical analysis was performed as
previously described.21 In brief, the immunoreactivities for Klotho,
FGFR1, and Ki67 antigen were evaluated in six areas that were
randomly selected by one observer. The Klotho and FGFR1 signals
were scored according to the percentage of positive staining along
the cell surface using the following grading criteria: grade 3, more
than 75%; grade 2, 50–75%; grade 1, 25–50%; and grade 0, below
25% (Figure 1). The number of Ki67-positive cells in each area,
counted at a magnification of  200, was designated as the Ki67
score. This analysis was performed by three independent observers
(the intra- and inter-observer coefficients of variation were all
o10%). After taking an average of the scores, Klotho, FGFR1, and
Ki67 scores were assigned to each gland.
RNA isolation and quantitative real-time reverse
transcription PCR
Parathyroid tissues were immediately freeze-dried in liquid nitrogen
and stored at 80 1C until RNA isolation. Total RNA was isolated
using Isogen (Nippon Gene, Tokyo, Japan). First-strand cDNA was
synthesized using a TaKaRa RNA PCR kit (AMV) (Takara
Biochemicals, Osaka, Japan). Quantitative real-time PCR analysis
was performed by using the Bio-Rad CFX96 Real-Time PCR
Detection System (Bio-Rad, Hercules, CA, USA) and the FastStart
Universal SYBR Green Master mix (Roche, Indianapolis, IN, USA).
The relative gene expression was normalized to the gene expression
of glyceraldehyde 3-phosphate dehydrogenase in the same sample.
Sequences of primers used for quantitative real-time reverse
transcription PCR are listed in Table 2. Specificity of the PCR
products was verified by melting curve analysis and agarose gel
electrophoresis.
Laboratory methods
Blood samples were obtained 1 or 2 days before parathyroidec-
tomy. Samples were stored foro2 h at 5 1C until centrifugation. On
arrival at the laboratory, the blood samples were centrifuged at
3000 r.p.m. for 10min, aliquoted, and stored at 80 1C until
analysis. Serum PTH(1–84) levels were measured using a third-
generation PTH assay (Whole PTH; Scantibodies Laboratories,
Santee, CA, USA). Serum FGF23 levels were determined using a
sandwich ELISA kit (Kainos Laboratories, Tokyo, Japan) that
exclusively detects the full-length FGF23 peptide. Serum calcium,
phosphorus, albumin, alkaline phosphatase, blood urea nitrogen,
and creatinine were measured using standard methods. The
measured serum calcium levels were adjusted to albumin levels
using the following equation: corrected calcium¼ serum measured
calciumþ (4albumin).
Statistical analysis
All values are expressed as means±s.e.m. Statistical significance
was determined by Student’s t-test and Fisher’s exact test for two-
group comparisons and by one-way ANOVA (analysis of variance)
for multiple-group comparison followed by Bonferroni’s post-hoc
test. Pearson’s correlation coefficient analyses were used to examine
the relationships between each parameter. Po0.05 was conside-
red statistically significant. All computations were performed
using Dr SPSS II for Windows version 11.01 J (SPSS Japan, Tokyo,
Japan).
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